

# Characterisation of the lung virome in patients with Legionnaires’ disease

M. IBRANOSYAN<sup>1,2</sup>, C. GINEVRA<sup>1,2</sup>, B. SIMON<sup>3</sup>, G. DESTRAS<sup>3,4</sup>, H. REGUE<sup>3</sup>, C. ALLAM<sup>1,2</sup>, L. BERAUD<sup>1</sup>, A. BAL<sup>3,4</sup>, G. DESCOURS<sup>1,2</sup>, L. JOSSET<sup>3,4</sup>, S. JARRAUD<sup>1,2</sup>

<sup>1</sup> Hospices Civils de Lyon, Centre National de Reference des légionelles, Lyon, France

<sup>2</sup> CIRI, Centre International de Recherche en Infectiologie, LEGIOPATH team, Inserm, U1111, CNRS, UMR5308, Université Lyon 1, École Normale Supérieure de Lyon, Lyon, France

<sup>3</sup> Hospices Civils de Lyon, Centre National de Reference des Virus Respiratoires, Lyon, France

<sup>4</sup> CIRI, Centre International de Recherche en Infectiologie, VIRPATH team, Inserm, U1111, CNRS, UMR5308, Université Lyon 1, École Normale Supérieure de Lyon, Lyon, France

## Introduction

Legionnaires’ disease (LD) due to the bacterium *Legionella* is a pneumonia for which mortality remains high (10%, up to 30%). Only few studies have explored the lung bacteriome of LD patients<sup>1,2</sup> and data on the lung virome are still lacking.

## Aim

We aimed to characterise the diversity, richness and composition of the lung virome at the initial time and during the course of LD, and to determine whether viral signatures were associated with characteristics of LD patients.


## Material & methods

We performed a shotgun viral metagenomic process adapted from Bal et al.<sup>3</sup> on 63 lung samples collected at the initial time (n=33) and during follow-up time points (n=30, from day 3 (D3) to D21) from 33 patients with LD enrolled in the french cohort ProgLegio.


### Viral metagenomic process

- |                                                                                                                                                                                                                                                                                  |  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| <p><b>Sample types (n=63)</b></p> <ul style="list-style-type: none"> <li>23 sputa</li> <li>38 tracheobronchial aspirates (TBA)</li> <li>2 bronchoalveolar lavages (BAL)</li> </ul>                                                                                               |  |
| <p><b>1. Fluidification</b></p> <ul style="list-style-type: none"> <li>Dithiothreitol (v/v)</li> </ul>                                                                                                                                                                           |  |
| <p><b>2. Viral enrichment</b></p> <ul style="list-style-type: none"> <li>Centrifugation 6000G 10 min</li> <li>RNA internal quality control (IQC) + DNA IQC</li> <li>Filtration 0,8µm</li> <li>Dilution (1:4 BAL &amp; sputa; 1:10 TBA)</li> <li>TURBO™ DNase 37°C 90’</li> </ul> |  |
| <p><b>3. Total nucleic acids extraction</b></p> <ul style="list-style-type: none"> <li>MagNA Pure 24 System (Roche)</li> <li>Ethanol precipitation</li> </ul>                                                                                                                    |  |
| <p><b>4. Random amplification</b></p> <ul style="list-style-type: none"> <li>WTA2 (Whole Transcriptome Amplification)</li> <li>Spin column-based purification</li> </ul>                                                                                                         |  |
| <p><b>5. Library / Sequencing</b></p> <ul style="list-style-type: none"> <li>Nextera XT / Nextseq 2*150 bp Illumina</li> </ul>                                                                                                                                                   |  |
| <p><b>6. Bioinformatic analyses</b></p> <ul style="list-style-type: none"> <li>Pipeline (aligning softwares: bwa mem, DIAMOND)</li> </ul>                                                                                                                                        |  |


### Less diversity of virome in TBA/BAL than in sputa



### Low viral diversity and richness in samples collected lately after the onset of LD symptoms




### Trend of low viral richness in respiratory samples with high Legionella load



## Results

### Less richness of virome in TBA/BAL than in sputa




### Eight viral families were significantly more prevalent in sputum than in TBA/BAL

**Papillomaviridae** (73% vs 6%,  $p=0.0001$ )  
**Herpesviridae** (73% vs 11%,  $p=0.0004$ )  
**Siphoviridae** (87% vs 28%,  $p=0.0013$ )  
**Alphaflexiviridae** (47% vs 0%,  $p=0.0015$ )  
**Circoviridae** (53% vs 11%,  $p=0.02$ )  
**Picobirnaviridae** (53% vs 11%,  $p=0.02$ )  
**Phycodnaviridae** (40% vs 6%,  $p=0.03$ )  
**Polyomaviridae** (27% vs 0%,  $p=0.03$ )

### Herpesviridae reactivations highlighted in 21 LD patients

- Overall, *Herpesviridae* reads were detected in 48% (30/63) samples corresponding to 64% (21/33) of LD patients
- We had follow-up samples from D3 to D21 for 16 patients
  - At D0
    - **80% (4/5) were *Herpesviridae*-positive in sputa**
    - None (0/11) were *Herpesviridae*-positive in TBA/BAL
  - Between D3-D21
    - **100% (5/5) were *Herpesviridae*-positive in sputa**
    - **64% (7/11) were *Herpesviridae*-positive in TBA/BAL**, orotracheal intubation was reported in 78% (6/7) of them

### A total of 27 viral families found in LD respiratory samples



## Conclusions

- Lung virome data during the course of LD showed a large variety of viral families and are depending on sample type.
- A *Herpesviridae* reactivation was observed for 21 patients (64%), among them 8 became positive during the follow-up. Reactivations of *Herpesviridae* according to the site of the reactivation (sputum or TBA/BAL) could be related to immunosuppression and/or orotracheal intubation.
- Low viral diversity and richness was found in late initial samples, which could be impacted by the lung load of *Legionella* and by the immune response to the bacterial infection.

## References

- Mizrahi H, et al. Sci Rep. 2017;7(1):40114.
- Pérez-cobas AE, et al. MBio. 2020;11(3):1–14.
- Bal A, et al. BMC Infect Dis. 2018;18(1):1-10.

## Contact information

Prof. Sophie JARRAUD: sophie.jarraud@univ-lyon1.fr